Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory

Pediatric Infectious Disease Journal

Volumn 17, Issue 3, 1998, Pages 211-216

  Åhman, Heidi ^a   Käyhty, Helena ^a   Lehtonen, Hannele ^a   Leroy, Odile ^b   Froeschle, James ^c   Eskola, Juhani ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b Pasteur Merieux Connaught   (France)

^c Connaught Laboratories ^*  (United States)

Author keywords

Immunogenity; Infants; Pneumococcal diphtheria toxoid conjugate vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEXACYCLINE; IMMUNOGLOBULIN G; MEASLES MUMPS RUBELLA VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; TETANUS TOXOID;

ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MIXTURE; ENZYME IMMUNOASSAY; GOOD CLINICAL PRACTICE; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFANT; INTRAMUSCULAR DRUG ADMINISTRATION; NORMAL HUMAN; PRACTICE GUIDELINE; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY IMMUNE RESPONSE; STREPTOCOCCUS PNEUMONIAE;

ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; DIPHTHERIA TOXOID; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOLOGIC MEMORY; INFANT; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 0345215181     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199803000-00008     Document Type: Article

References (23)

1. Cohen J. Bumps on the vaccine road. Science 1994;265: 1371-3
2. Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990;3:171-96.
3. Breiman KF, Butler J, Tenover F, et al. Emergence of drug-resistant pneumococcal infections in United States. JAMA 1994;23:1831-5.
4. Käyhty H, Åhman H, Rönnberg PR, Tillikainen R, Eskola J. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J Infect Dis 1995;172:1273-8.
5. Quataert SA, Kirch CS, Quackenbush Wiedl LJ, et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, Lot 89-S. Clin Diagn Lab Immunol 1995;2:590-7.
6. Anderson EL, Kennedy DJ, Geldmacher KM et al. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr 1996;128:649-53.
7. Åhman H, Käyhty H, Tamminen P, Vuorela A, Malinoski F, Eskola J. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr Infect Dis J 1996;15: 134-9.
8. Insel RA. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components [Review]. Ann NY Acad Sci 1995;754:35-47.
9. Leach A, Ceesay SJ, Banya WAS, et al. Pilot trial of a pentavalent polysaccharide/protein conjugate vaccine in Gambian infants. Pediatr Infect Dis J 1996;15:33-9.
10. Leinonen M, Säkkinen A, Kalliokoski R, Luotonen J, Timonen M, Mäkelä PH. Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in preschool age children. Pediatr Infect Dis 1986;5:39-44.
11. Mäkelä PH, Karma P, Sipilä M, Pukander J, Leinonen M. Possibilities of preventing otitis media by vaccination. Scand J Infect Dis Suppl 1983;39:34-8.
12. Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to Class II-restricted T lymphocytes. Annu Rev Immunol 1990;8:773-93.
13. Giebink GS, Koskela M, Vella PP et al. Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media. J Infect Dis 1993; 167:347-55.
14. Alonso De Velasco E, Dekker BAT, Verheul AFM, et al. Antipolysaccharide immunoglobulin isotype levels and opsonic activity of antisera: relationships with protection against Streptococcus pneumoniae infection in mice. J Infect Dis 1995;172:562-5.
15. Riley ID, Alpers M, Gratten H, Lehmann D, Marshall TFDC, Smuth D. Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children. Lancet 1986;2:8:77-81.
16. Shurin PA, Giebink GS, Wegman DL, et al. Prevention of pneumococcal otitis media in chinchillas with human bacterial polysaccharide immune globulin. J Clin Microbiol 1988; 26:755-9.
17. Santosham M, Reid GR, Almeido-Hill J, et al. Efficacy of bacterial polysaccharide immune globulin (BPIG) for prevention of bacteremic pneumococcal infections in Apache children. Pediatr Res 1992;31:178A.
18. Shurin PA, Rehmus JM, Johnson CE, et al. Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high risk children. J Pediatr 1993;123:801-10.
19. Rubin LG, Mardy GV, Pais L, Carlone G. Human anticapsular antibody concentration required for protection against experimental pneumococcal bacteremia [Abstract G47]. Presented at the 35th Interscience Conference of Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17 to 20, 1995.
20. Saladino RA, Stack AM, Malley R, Thompson CM, Siber CR, Fleiser GO. Bacterial polysaccharide immune globulin (BPIG) protects infant rats with S. pneumoniae (SP) pneumonia from bacteremia, meningitis and death. Pediatr Res 1996;36:184A.
21. Eskola J, Käyhty H, Takala A, et al. A randomized prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl Med 1990;323:1381-7.
22. Käyhty H, Eskola J, Peltola H, Saarinen L, Mäkelä PH. High antibody responses to booster doses of either Haemophilus influenzae capsular polysaccharide or conjugate vaccines after primary immunization with conjugate vaccines. J Infect Dis 1992;165(Suppl 1):S165-6.
23. Reid R, Santosham M, Croll J, Thompson C, Newcomer W, Siber G. Antibody response of Navajo children primed with PRP-OMP vaccine to booster doses of PRP-OMP vs. HbOC vaccine. Pediatr Infect Dis J 1993;12:812-15.